ReconRegulatory

Medacta receives approval in Japan for MyShoulder Placement Guides

Castel San Pietro, 24 July 2019 – Medacta International will soon introduce the MyShoulder Placement Guides for shoulder arthroplasty in the Japanese market after it has successfully obtained the Pharmaceutical and Medical Device Agency (PMDA) approval.

After the recent launch of its shoulder implants in Japan, Medacta is further expanding the shoulder product offerings with the MyShoulder Placement Guides.

These patient-specific, 3D-printed solutions work in conjunction with the Medacta Shoulder System and associated instrumentation to create a precise surgical approach specific to each patient’s individual anatomy. It is composed by two guides and a WebPlanner. The two guides, a humeral cutting guide and a glenoidal reaming guide, assist the surgeon optimizing the accuracy and reducing the surgery time. The WebPlanner allows the surgeon to carry out a precise preoperative planning.

The MyShoulder platform is part of the sophisticated “MySolutions” technology. Thanks to the creation of advanced personalized kinematic models and 3D planning tools, MySolutions are highly personalized pre-operative planning and implant placement methodologies for use not only in shoulder procedures, but also in hip (MyHip), knee (MyKnee) and spine (MySpine) procedures.”The development of highly patient-personalized pre-operative planning and implant placement methodologies using our MySolutions technology has been one of our key innovations” said Francesco Siccardi, CEO of Medacta International. “The introduction of the MyShoulder system is an important step to further expand our activities in the Japanese market.”For more information, please visit the MyShoulder webpage at https://www.medacta.com/EN/medacta-shoulder-system-global.

Inquiries
Corrado Farsetta
Medacta Group SA
CFO
Phone: +41 91 696 60 60
investor.relations@medacta.ch

About Medacta 
Medacta is an international orthopaedics company specializing in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta’s products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of the minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (“AMIS”) technique for hip replacements. Medacta has leveraged its orthopedic expertise and comprehensive understanding of the human body to develop the sophisticated “MySolutions” technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures. Medacta is headquartered in Castel San Pietro, Switzerland, and employs approximately 970 people. To learn more about Medacta, please visit www.medacta.com
End of ad hoc announcement
Language:English
Company:Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone:+41 696 6060
E-mail:info@medacta.ch, investor.relations@medacta.ch
Internet:www.medacta.com
ISIN:CH0468525222
Listed:SIX Swiss Exchange
EQS News ID:845581

End of AnnouncementEQS Group News Service

845581  24-Jul-2019 CET/CEST

Tags

Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button